1. Scrip
  2. >>Drug Pricing

Obesity Gold Rush To Drive Significant Spending Growth Through Decade, IQVIA Says

 
• By Alaric DeArment

IQVIA’s latest usage and spending trends report forecasts US obesity market will grow to $35bn by 2028, while the two leading GLP-1 agonists have already posted eye-popping sales growth.

• Source: Shutterstock

One of the most important stories in the biopharma industry has been the rise of GLP-1 agonists for treating obesity. Novo Nordisk A/S’s GLP-1 agonist Ozempic/Wegovy (semaglutide) and Eli Lilly and Company’s GIP/GLP-1 agonist Mounjaro/Zepbound (tirzepatide) are taking a dominant role in the drug market overall and will likely continue to be a major driver of sales over the next several years, according to IQVIA’s latest medication usage report.

The report, released on 7 May, found that the US prescription drug market at net prices grew overall to $435bn...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Indegene Exec On DTP Distribution As A ‘Tactical Solution’, Feasibility Of MFN Model

 
• By Anju Ghangurde

Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US and underlines that it isn’t a comprehensive healthcare fix. Feasibility of MFN pricing and why it may be “catastrophic” to the industry were some of the other topics discussed.

Lilly Begins Rebalancing US/Ex-US Drug Costs By Raising Prices In Europe

 
• By Mandy Jackson

Lilly said prices governments pay in developed countries, including those in Europe, need to increase to make US drug prices lower, rebalancing costs as CEO David Ricks recently advocated.

Lilly CEO Ricks Advocates Rebalancing Drug Pricing Between US And Europe

 
• By Mandy Jackson

As President Trump focuses on “most favored nation” pricing to bring down US drug costs, CEO David Ricks used Lilly’s Q2 earnings call to advocate for a slow approach to reducing the difference between US and EU drug prices.

Pharma Is Cooperating With Trump On Direct Sale To Consumers, Bourla Says

 
• By Jessica Merrill

Pfizer is in active discussions with Trump on MFN pricing and collaborating with peers on direct sales as an approach to lower drug prices, CEO Bourla said.

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: a look at the likely top drugs in 2030; Lilly CEO advocates US/Europe pricing rebalance; Insmed sees $5bn-plus market for Brinsupri; royalty deals go mainstream; Phase III win sets stage for Epkinly label expansion.

Finance Watch: Did Mid-Summer Usher In A Mega-Round Comeback?

 
• By Mandy Jackson

Private Company Edition: Hatteras Venture Partners now has more than $900m under management. Also, in recent $100m-plus VC rounds, Strand Therapeutics raised a $153m series A, ARTBIO revealed a $132m series B and Minghui Pharmaceutical secured a $131m pre-IPO round.

Tonix Ready To Revive Fibromyalgia Market With Tonyma

 
• By Joseph Haas

The first new drug for fibromyalgia since 2009, Tonyma is a reformulation of cyclobenzaprine intended for chronic therapy. Tonix said the drug targets non-restorative sleep.